Antibody-Drug Conjugates: Bridging Precision and Potency in Oncology

Antibody-drug conjugates (ADCs) are reshaping the landscape of oncology by offering highly targeted cancer therapies with enhanced specificity, reduced toxicity and improved efficacy. However, the development of ADCs remains complex, with challenges that include optimizing drug delivery, overcoming resistance and identifying the right patient populations for treatment.

This webinar will explore how recent advancements in bioconjugation technology and multi-omics approaches are driving the next generation of ADCs from preclinical evaluation to clinical application.

Attendees will gain key insights into how cutting-edge preclinical models, such as patient-derived xenografts (PDX) and 3D organoids, can more accurately reflect human tumor biology and resistance mechanisms. By integrating these models into the drug development process, researchers can gain a deeper understanding of ADCs’ efficacy, optimize therapeutic design and accelerate the transition from preclinical to clinical stages.

This webinar will also highlight the critical role of multi-omics approaches in the development of ADCs. Advanced bioinformatics tools, combined with proteomics and genomics data, allow for the identification of potential biomarkers, enabling precise patient stratification and enhancing clinical trial success. This data-driven approach not only improves therapeutic outcomes of ADCs but also opens up new avenues for personalized medicine.

Peng Wang, PhD will also discuss strategies for target and indication identification, focusing on how ADCs can be effectively combined with immuno-oncology therapies. These combination strategies are becoming increasingly important in the fight against cancer, as they offer the potential to overcome resistance and enhance the overall therapeutic effect. Dr. Wang will share real-world examples of how these approaches are being applied in current drug development pipelines, offering valuable insights for pharmaceutical and biotech professionals.

Whether you’re interested in early-stage ADCs’ discovery, preclinical evaluation or clinical trial design, this webinar will provide actionable knowledge to help overcome key challenges and accelerate the development of novel ADC-based therapies.

Register for this webinar today to understand how innovative preclinical models and advanced multi-omics approaches can enhance the development of ADCs, streamline clinical success and unlock the potential for personalized cancer treatments. Don’t miss this opportunity to learn from industry experts and stay at the forefront of oncology drug development!

Speaker

Peng Wang, PhD, Executive Director, Scientific Operations, Crown Bioscience

Peng Wang is responsible for cell line construction, organoid development, in vitro assays and antibody discovery at Crown Bioscience. Dr. Wang holds a PhD in Biological Sciences from the University of Delaware and completed a postdoctoral fellowship in Immunology at the University of Pennsylvania’s Perelman School of Medicine.

Dr. Wang formerly worked at Roche (China) and WuXi AppTec, with over 15 years of experience in biomedical research and drug development.

Message Presenter